Sarepta Therapeutics, Inc. (SRPT): "You Don't Court Homicide," Says Jim Cramer
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has had a controversial time on the stock market in July.
Sarepta Therapeutics Inc. (SRPT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $134.66 | 5,648 | $760,559.68 | 284,034 | 2024-08-16 | Filing | |
| $134.06 | 18,284 | $2,451,153.04 | 278,386 | 2024-08-16 | Filing | |
| $133.07 | 13,106 | $1,744,015.42 | 260,102 | 2024-08-16 | Filing | |
| $78.81 | 40,000 | $3,152,400.00 | 140,000 | 2023-11-03 | Filing | |
| $78.81 | 10,000 | $788,100.00 | 10,000 | 2023-11-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.64 | 2,491 | $248,203.24 | 27,812 | 2025-03-12 | Filing | |
| $124.84 | 10,500 | $1,310,820.00 | 22,840 | 2024-12-12 | Filing | |
| $125.55 | 1,636 | $205,399.80 | 5,880 | 2024-12-05 | Filing | |
| $137.36 | 5,985 | $822,099.60 | 33,946 | 2024-08-30 | Filing | |
| $164.52 | 2,549 | $419,361.48 | 17,129 | 2024-06-25 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,160,179 | $156,639,062 | 0% | |
| 2. | 1,875,997 | $32,084,853 | 0% | |
| 3. | 42,484 | $30,694,690 | 1.04% | |
| 4. | 37,821,000 | $27,917,571 | 0.11% | |
| 5. | 1,242,404 | $21,499,801 | 0.04% |
News See All
11 Stocks That Jim Cramer Recently Talked About
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed why fighter and bomber pilots lead to high defense spending.
BMO Capital Cuts Sarepta Therapeutic (SRPT) PT to $25 from $50
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the most undervalued stocks to buy and hold for 3 years.
10 Most Undervalued Stocks to Buy and Hold for 3 Years
On July 17, Lori Calvasina, RBC Capital Markets head of US equity strategy, joined 'Closing Bell' on CNBC to discuss whether the market is fully valued at present levels.
Sarepta Therapeutics (SRPT): "They Should Be Prosecuted," Says Jim Cramer
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a biotechnology company that focuses on gene-based therapies.
12 Stocks Jim Cramer Discussed As Analyzed Morgan Stanley's Comments
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed a note by Morgan Stanley's Mike Wilson, which outlined that the market could be held up by AI, operating leverage could be enhanced...
Sarepta (SRPT) Jumps Nearly 20% on Corporate Restructuring
Sarepta Therapeutics saw its share prices rise by 19.53 percent on Thursday to close at $21.97 apiece following announcements that it would shift its focus to high-impact programs as part of a corporate...
10 Best Small-Cap Stocks to Buy According to Billionaires
On Tuesday, the Dow Jones Industrial Average dropped 0.98%, mainly because of worries about rising US inflation and mixed earnings reports from big banks.
Sarepta Therapeutics Halts ELEVIDYS Shipments for Non-Ambulatory DMD Patients
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best low priced pharma stocks to buy now.
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory
We came across a bullish thesis on Sarepta Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this article, we will summarize the bulls’ thesis on SRPT.